Semaglutide: what is legal, and what is being sold
The short answer
Semaglutide is FDA-approved in the United States, so the drug itself is legal to prescribe. It is also not on the 503A Bulks List, which is what governs whether a pharmacy may compound its own version — and that is the question worth asking here, as of 2026-08-29. The Pharmacy Compounding Advisory Committee has never considered it, so there is no vote to report — it is investigational, and the routes to it are set out below.
What FDA actually evaluated
FDA assessed Semaglutide for one thing: type 2 diabetes (ozempic, rybelsus) and chronic weight management (wegovy), each with its own labelled population and dosing..
Cosmetic or modest weight loss in people who do not meet the labelled criteria, and every use of a compounded copy — which by definition carries no approved labelling at all.
Full regulatory status
| FDA-approved drug? | Yes. Novo Nordisk markets FDA-approved semaglutide products in the US — Ozempic and Rybelsus, both confirmed in Drugs@FDA, and Wegovy under NDA 215256. Approval is by product and indication, never for a molecule at large. |
|---|---|
| What has been evaluated | Type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy), each with its own labelled population and dosing. |
| PCAC recommendation | Never considered — no nomination has reached the committee |
| FDA reviewers' position | Not applicable. Semaglutide is an approved drug, so it has never been before the Pharmacy Compounding Advisory Committee, which considers bulk substances nominated for compounding rather than approved products. |
| Category 2 status | Not applicable. FDA's interim 503A categories cover bulk substances nominated for compounding. Semaglutide is an approved drug and is not on the 503A Bulks List. |
| 503A Bulks List today | Not on the 503A Bulks List, and it does not need to be — the barrier to compounding an approved drug is a different one. Section 503A(b)(1)(D) stops a pharmacy regularly compounding a drug that is essentially a copy of a commercially available product. While semaglutide injection was in shortage that restriction was relaxed; FDA determined the shortage resolved on 21 February 2025 and gave 503A pharmacies until 22 April 2025 to stop. That date has passed. |
| 503B status | Not on the 503B Bulks List. FDA gave outsourcing facilities until 22 May 2025 to stop compounding semaglutide injection products that are essentially a copy of an approved drug. That date has passed, and with semaglutide off the shortage list there is no bulk-substance route back. |
| Prescription status | Prescription-only, and the lawful version is the approved product from a pharmacy. Compounding did not become illegal in every case: a prescriber can still document that a specific patient needs a change from the approved product that makes a significant difference for them, and FDA has stated a non-action policy for pharmacies compounding four or fewer prescriptions a month. What ended is the mass-market business of selling compounded semaglutide as a cheaper equivalent. |
| Next federal event | Rybelsus tablets are listed in FDA's shortage database as “To Be Discontinued” as of 4 June 2026, with Novo replacing them with Ozempic-branded semaglutide tablets. Discontinuing one brand does not by itself reopen compounding: commercial availability of the drug, and the patient-specific significant-difference test, still control. |
If you compete in sport
No substance-specific WADA determination for semaglutide was located. That means none was found, not that it is permitted — a tested athlete should get it in writing from their anti-doping authority.
We could not find a substance-specific ruling. Treat this as unknown, not as permission, and check with your governing body before use.
Why FDA's own reviewers recommended against it
What you can actually do today
Much of what is sold online as semaglutide is neither the approved product nor a lawfully compounded one, and FDA has been acting on it through 2026. On 6 February 2026 it announced it intends to restrict GLP-1 active ingredients going into non-approved compounded drugs mass-marketed as alternatives. On 3 March 2026 it warned 30 telehealth companies over illegal marketing of compounded GLP-1s. On 14 April 2026 it wrote to New Life Pharma about semaglutide and tirzepatide sterile multi-dose vials as unapproved new drugs. FDA also publishes guidance aimed specifically at telehealth companies promoting compounded drugs. If a website will sell you semaglutide without a prescriber documenting why the approved product will not do, that is the market those actions describe.
What would have to happen for this to change
- 1FDA completes its own evaluation. The advisory vote is non-binding — FDA can accept or reject it.
- 2FDA publishes a proposed rule in the Federal Register identifying substances proposed for inclusion or exclusion, with its reasoning.
- 3A public comment period opens. Anyone may submit evidence and scientific or legal objections.
- 4FDA reviews the comments and the administrative record.
- 5FDA publishes a final rule, or withdraws or modifies the proposal.
- 6The final rule takes effect and amends the list at 21 CFR 216.23.
Sources
- Drugs@FDA — Ozempic and Rybelsus (openFDA)
- Drugs@FDA — Wegovy, NDA 215256
- FDA — clarifies policies for compounders as GLP-1 supply stabilizes (source of every date above)
- FDA — FD&C Act provisions that apply to human drug compounding
- FDA — intends to take action against non-FDA-approved GLP-1 drugs, 6 Feb 2026
- FDA — warns 30 telehealth companies, 3 Mar 2026
- FDA warning letter, New Life Pharma, 14 Apr 2026
- FDA — what telehealth companies should know when promoting compounded drugs
- FDA 503B Bulks List
See the status of all seven peptides side by side in the FDA 503A compounding tracker. Or read our full guide to Semaglutide.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.